Showing 1189 results
- Media Release /New Cosentyx® (secukinumab) label to include dosing flexibility up to 300 mg, based on clinical response, and 24-week structural data with subcutaneous (sc) regimens[1] Cosentyx inhibits…
- Media Release /SMART Suite by Alcon will drive innovation in ophthalmology delivering personalized and seamless end-to-end care for cataract patients As an open, secure cloud-enabled ecosystem, SMART…
- Media Release /The LIBERTY trial is the first study of a CGRP-targeted therapy in a patient population where multiple preventive treatments had previously failed Patients treated with Aimovig, reported…
- Media Release /Extended follow up results confirm leading BRAF/MEK inhibitor combination Tafinlar + Mekinist continues to show relapse free survival benefit Cure rate modeling which estimates fraction of…
- Media Release /Global headquarters to be co-located in Geneva alongside Alcon's Europe, Middle East and Africa regional office The listed Alcon company will be incorporated in Fribourg, where Alcon already has…
- Media Release /Der globale Hauptsitz wird räumlich zusammen mit dem Alcon Regionalbüro für Europa, den Nahen Osten und Afrika in Genf eingerichtet Das börsennotierte Unternehmen Alcon wird in Fribourg…
- Media Release /Le siège social mondial sera basé à Genève à côté du bureau régional d'Alcon pour l'Europe, le Moyen-Orient et l'Afrique La société Alcon cotée en bourse sera enregistrée à Fribourg, où Alcon…
- Key Release /Novartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc. Agreement comprises the Sandoz US generic…
- Media Release /Data from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with the longest reported median overall survival (OS) in HR+/HER2-…
- Media Release /Results from year two of the Phase III KESTREL clinical trial confirmed year one findings, with an overall favorable benefit-risk profile for Beovu® (brolucizumab) 6 mg in patients with visual…
Pagination
- ‹ Previous page
- 1
- …
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- › Next page